XR 11576

Drug Profile

XR 11576

Alternative Names: MLN 576

Latest Information Update: 09 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Auckland Cancer Society Research Centre; Xenova Group
  • Class Antineoplastics
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Feb 2007 Discontinued - Phase-I for Cancer in Netherlands (PO)
  • 09 Feb 2007 Discontinued - Phase-I for Cancer in United Kingdom (PO)
  • 05 Apr 2006 No development reported - Phase-I for Cancer in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top